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Abstract To reduce long-term morbidity after revascular-
ised acute myocardial infarction, different therapeutic strate-
gies have been investigated. Cell therapy with mononuclear
cells from bone marrow (BMMC) or peripheral blood
(PBMC) has been proposed to attenuate the adverse processes
of remodelling and subsequent heart failure. Previous trials
have suggested that cell therapy may facilitate arrhythmo-
genesis. In the present substudy of the HEBE cell therapy
trial, we investigated whether intracoronary cell therapy alters
the prevalence of ventricular arrhythmias after 1 month or the
rate of severe arrhythmogenic events (SAE) in the first year. In
164 patients of the trial we measured function and infarct size
with cardiovascular magnetic resonance (CMR) imaging.
Holter registration was performed after 1 month from which
the number of triplets (3 successive PVCs) and ventricular
tachycardias (VT, ≥4 successive PVCs) was assessed.
Thirty-three patients (20%) showed triplets and/or VTs,
with similar distribution amongst the groups (triplets:
control n08 vs. BMMC n09, p01.00; vs. PBMC n0
10, p00.67. VT: control n09 vs. BMMC n09, p00.80;
vs. PBMC n011, p00.69). SAE occurred in 2 patients
in the PBMC group and 1 patient in the control group.
In conclusion, intracoronary cell therapy is not associ-
ated with an increase in ventricular arrhythmias or SAE.
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Introduction
Although the short-term mortality after acute myocardial
infarction has decreased over the last decades, long-term
morbidity remains high due to congestive heart failure
caused by post-infarction remodelling [1–3]. To reduce the
burden of chronic illness, new adjuvant treatment options
are being explored to attenuate these adverse processes.
Several experimental studies have suggested that cell
therapy may improve functional recovery in patients
after ST-elevation myocardial infarction (STEMI) due
to induction of neoangiogenesis and beneficial paracrine
effects, limiting adverse processes such as inflammation
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and remodelling [4]. More recent studies have suggested
that certain subsets of (bone marrow derived) mononu-
clear cells contribute to the repair by stimulating the produc-
tion of new cardiomyocytes from endogenous progenitor cells
[5]. However, critics of cell therapy have expressed their
concern regarding the safety of cell therapy, claiming that this
technique may be applied too quickly, without extensive
knowledge of all the possible effects of cell therapy.
Specifically, fear has been expressed regarding the potential
arrhythmogenic effects as was seen with the use of skeletal
myoblasts for cell therapy in patients with ischaemic cardio-
myopathy [6]. Multiple pro-arrhythmogenic properties of cell
therapy have been proposed, such as the induction of tissue
inhomogeneities, abnormal intercellular electrical coupling
and autonomic function, leading to pathways for slow and/or
unidirectional conduction [7, 8]. These unwanted effects of cell
therapy may form a substrate for the development of ventric-
ular arrhythmias, since it can provide the necessary conditions
for arrhythmogenesis (i.e. a tissue substrate to form a reentry
pathway, triggering factors and facilitating conditions) [9].
Between August 2005 and April 2008, the HEBE trial
was conducted to assess the effect of intracoronary infusion
with autologous mononuclear cells derived from either bone
marrow (BMMCs) or peripheral blood (PBMCs), compared
with standard therapy on recovery of regional and global left
ventricular function after a revascularised acute myocardial
infarction. The trial did not show an effect of either BMMCs
or PBMCs on functional improvement at short-term follow-
up [10]. To evaluate the safety of cell treatment, this sub-
study investigates the effect of intracoronary infusion of
BMMCs or PBMCs after revascularised acute myocardial
infarction on the prevalence of ventricular arrhythmias after
1 month and the occurrence of severe arrhythmogenic
events (SAE) in the first year.
The study design of the HEBE trial has been reported in
detail previously [11]. In short, patients between 30 and
75 years of age with a first STEMI treated with primary
PCI were included in this multicentre trial. Between 3 and
7 days after PCI, patients underwent cardiovascular mag-
netic resonance imaging (CMR). After successful CMR
imaging, patients were screened for eligibility and signed
informed consent. Participating patients were randomly
assigned in a 1:1:1 ratio to either additional intracoronary
infusion of BMMCs, intracoronary infusion of PBMCs, or
no cell therapy (i.e. only standard medical therapy). The
study was conducted in accordance with the Declaration of
Helsinki, and the study protocol was approved by the
Institutional Review Boards of the participating institutes.
Coronary angiography with subsequent intracoronary infu-
sion of mononuclear cells was performed in patients rando-
mised to BMMC and PBMC therapy, whereas no
angiography or cell therapy was performed in patients rand-
omised to the control group. The detailed cell processing
and cell characterisation protocols have been reported pre-
viously [11]. A 24-hour Holter registration was performed
1 month after PCI, together with a resting ECG. Clinical
follow-up was obtained at 1 month, 4 months and 1 year
after the index event. For this substudy, SAE was defined
as any event consisting of either sudden cardiac death
or documented ventricular arrhythmias for which exter-
nal defibrillation or ICD therapy was required.
Data acquisition and analysis
In all participating patients, CMR was performed at least
48 h after PCI in a clinical 1.5 Tesla MR scanner with the
use of a phased-array cardiac receiver coil. Functional imag-
ing was performed by using ECG-gated steady-state free
precession cine imaging with breath-holding, for the acquisi-
tion of short-axis images covering the entire left ventricle (i.e.
from base to apex). From these images, left ventricular vol-
umes were measured and ejection fraction (LV EF) calculated
[11]. Late gadolinium enhancement (LGE) images were
acquired 10–15 min after administration of a gadolinium-
based contrast agent (Dotarem, Guerbet, Villepinte, France),
using a 2-dimensional segmented inversion recovery gradient-
echo pulse sequence, with similar full short-axis coverage of
the left ventricle. Using the standard deviation (SD) method
with a threshold window setting of 5 SD above the average
signal intensity of unaffected myocardium, total infarct size
was quantified [12]. Analyses were performed with dedicated
software (MASS v.5.1 2010-EXP beta, Medis, Leiden, the
Netherlands) and the performing analysts were blinded to the
patient data during the analyses.
One month after PCI, 24-hour Holter registration was
performed. Analysis was done automatically by external
core laboratories, including analyses of the rhythm and
morphology of each individual complex (supraventricular,
AV nodal or ventricular). Results were manually verified.
The arrhythmias were defined as follows: triplet PVCs were
defined as a series of 3 successive ventricular complexes
with a maximal RR interval of less than 600 ms (i.e. fre-
quency of >100/min). Ventricular tachycardia (VT) was
defined as any series of 4 or more successive ventricular
complexes with a maximal RR interval of less than 600 ms
(i.e. frequency of >100/min). By correcting for the total
recording time, the mean number of triplets and/or ventric-
ular tachycardias per 24 h for each patient was calculated for
standardisation. Together with the Holter registration, a
resting 12-channel electrocardiogram (ECG) was made from
which the QRS width and corrected QT time (QTc) were
measured.
Statistical analyses were performed on the basis of the
intention-to-treat principle. Tests were performed using the
Standard Package for the Social Sciences (SPSS 15.0).
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Results
Of the initial 200 patients, paired sets of CMR data and
Holter data were available in 164 patients, with equal dis-
tribution amongst the treatment groups (BMMC n060,
PBMC n053, control group n051). No differences were
found in the baseline characteristics between the treatment
groups for infarct size, LV volumes or LV function
(Table 1). Likewise, electrolyte levels and the duration of
the QT interval were similar in the three groups (Table 1).
During the Holter registration at 1 month, 33 patients
showed either triplet PVCs, ventricular tachycardia or both.
Distribution was similar amongst the treatment groups for
both triplets (control n08 vs. BMMC n09, p01.00; vs.
PBMC n010, p00.67) and ventricular tachycardias (control
n09 vs. BMMC n09, p00.80; vs. PBMC n011, p00.69). In
these 33 patients, a median of 1 triplet (interquartile range,
IQR 1–3) per 24 h and a median of 1 ventricular tachycardia
(IQR 1–3) occurred during registration. Again, no differences
existed between the treatment groups (Fig. 1).
Of all 200 patients, 9 suffered from a severe arrhythmo-
genic event during the first year of follow-up. One patient
assigned to the PBMC group died of VF during the first year
of follow-up, 13 days after cell therapy; autopsy revealed an
in-stent thrombosis. Two patients had documented VF with
successful resuscitation without sequelae and received an ICD
implantation. One of these patients was also assigned to the
PBMC and suffered from VF a few hours after cell infusion.
The other patient was assigned to the control group and VF
occurred 3 days after randomisation. Additionally, 6 patients
received an ICD for primary prevention of late arrhythmias
due to a low EF as indicated by the guidelines of the European
Society of Cardiology [13]. No cases of appropriate ICD
discharge in these patients have been reported in the first year.
Table 1 Functional parameters, infarct size and arrhythmia parameters of the three treatment groups
Characteristic Total group
(n0164)
BMMC
(n060)
PBMC
(n053)
Control
(n051)
BMMC vs.
Control
PBMC vs.
Control
p-value p-value
Functional and infarct mass parameters
Days between primary PCI and MRI 3(3–4) 3(2–4) 3(3–4) 3(3–5) 0.79 0.81
End-diastolic volume (ml•m-2) 98±16 97±14 98±16 100±17 0.39 0.50
End-systolilc volume (ml•m-2) 57±15 55±15 57±15 59±15 0.20 0.37
Left ventricular ejection fraction (%) 43±9 44±9 43±8 41±8 0.14 0.37
Infarct mass (% of LV mass) 19%±9% 19%±10% 18%±9% 20%±10% 0.57 0.30
Arrhythmia parameters
Duration of Holter (hours) at 1 month 24(23–25) 24(23–25) 24(23–24) 24(23–26) 0.76 0.052
QRS duration (ms) at 1 month 94(86–100) 92(83–100) 94(87–100) 96(88–100) 0.08 0.32
Corrected QT interval (QTc) at
1 month
420±27 418±29 418±28 423±24 0.37 0.33
Serum sodium level (mMol•L-1) at
1 month
141±2 141±2 141±2 142±2 0.40 0.01
Serum potassium level (mMol•L-1)
at 1 month
4.3±0.3 4.4±0.4 4.3±0.3 4.3±0.3 0.55 0.87
Class II anti-arrhythmic drug use
during Holter (%)
157 96% 55 92% 49 92% 50 98% 0.22 0.36
Patients with triplet PVCs (%) 27 16% 9 15% 10 19% 8 16% 0.92 0.67
Patients with ventricular tachycardias
(>4 PVCs) (%)
29 18% 9 17% 11 21% 9 15% 0.70 0.69
Patients with both triplet PVCs
and ventricular tachycardias (%)
13 8% 4 7% 6 11% 3 6% 1.00 0.49
No. of triplet PVCs/24 h (when
present)
1 (1–3) 2 (1–4) 1 (1–1) 2 (1–3) 0.74 0.42
No. of ventricular tachycardias
(when present)
1 (1–3) 1 (1–3) 2 (1–3) 1 (1–3) 0.69 0.73
BMMC 0 Bone marrow-derived mononuclear cells, PBMC 0 peripheral blood-derived mononuclear cells, PCI0percutaneous coronary interven-
tion. P-values are calculated by comparing treatment group vs. control. Data presented as mean ± standard deviation or as median (interquartile
range)
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Discussion
This HEBE trial substudy focused on the safety of cell therapy
with mononuclear cells after a revascularised STEMI, with
regard to arrhythmogenesis and the prevalence of SAE,
defined as either sudden cardiac death or documented
ventricular arrhythmias for which external defibrillation or
ICD therapy was required. One month after PCI and cell
therapy, the amount of triplet PVCs or ventricular tachycardias
are similar between the three treatment groups. Secondly, no
significant differences were found in the rate of severe
arrhythmogenic events in the first year of follow-up. This
shows that the current method of cell therapy, i.e. intracoro-
nary infusion of mononuclear cells, does not harbour an
increased risk of arrhythmogenesis. The choice to discrimi-
nate between triplet PVCs and ventricular tachycardia was
made in line with the results of the recently published
MERLIN-TIMI 36 substudy. This study demonstrated that
ventricular arrhythmias of 4 beats or more are associated with
worse prognosis [14]. Our findings are in concordance with
earlier cell therapy trials that did not report an increase in
arrhythmias or adverse events either while using similar cell
types and techniques as the HEBE trial [15, 16]. Vice-versa,
the contradictions with earlier findings regarding increased
arrhythmogenesis after cell therapy are most likely due to
the use of a different cell type [6, 17, 18]. For instance, these
studies used skeletal myoblasts instead of mononuclear
cells from either bone marrow or peripheral blood. An
animal study by Leobon et al. showed that transplanted
skeletal myoblasts do not show electrical coupling with
cardiomyocytes after differentiation and are functionally
isolated from the surrounding tissue [8]. Myoblasts dif-
ferentiate locally in cardiomyocyte-like cells, which are
electrically active, whereas mononuclear cells are not
electrically active and promote repair by promoting neo-
angiogenesis and endogenous repair by local progenitor
cells [4, 5]. Furthermore, the skeletal myoblasts were
grafted directly into the myocardial scar by intramyo-
cardial injection during CABG, whereas the HEBE trial used
intracoronary infusion of the revascularised infarct-related
artery. Theoretically, the intramyocardial injection is more
reliable in ensuring that the stem cells reach the intended
target, but it could also lead to a more pronounced disruption
of the tissue structure due to secondary myocardial damage
associated with direct injection of cell cultures.
An important issue that needs to be addressed is that no
positive effects of cell therapy have been found for the main
endpoints of the HEBE trial [10]. Therefore, it remains unclear
whether cell therapy has any influence on human myocardial
tissue in a clinical setting. The main results of the HEBE trial
demonstrate that cell therapy has no additional effect on the
recovery of myocardial function after a revascularised acute
myocardial infarction [10]. Recently, a HEBE trial flow-
Doppler substudy showed that the method of cell therapy did
not improve the microcirculation either [19]. It is possible that
cell therapy with mononuclear cells has more subtle effects on
the recovery processes after an acute myocardial infarction
than recovery of systolic function. As is known from theory of
the ischaemic cascade,many adverse processes (e.g. metabolic
changes, impaired perfusion and impaired diastolic function)
precede the disruption of systolic function [20]. It was recently
shown that a subpopulation of bone marrow derived mononu-
clear cells (C-Kit+ cells) may have an additional effect on the
endogenous repair processes by stimulating local progenitor
cells [5]. The amount of C-Kit+ cells within the administered
cell suspensions that were used in the HEBE trial is not
known. Secondly, the role of C-Kit+ cells in myocardial repair
after AMI in humans is still unknown. Future research on
different subpopulations of mononuclear cells and their ability
to induce neovascularisation, attenuating the inflammatory
response or stimulating local progenitor cells, all essential
parameters for determining whether functional improvement
is needed in order to appreciate a broader range of effects of
mononuclear cell therapy in humans.
Conclusion
Cell therapy by intracoronary infusion of mononuclear cells is
not associated with either an increase or decrease in the amount
of triplets or ventricular tachycardias. Secondly, no increased
incidence in severe arrhythmogenic events was found in the
first year of follow-up. Therefore, cell therapy consisting of
BMMC PBMC Control
0
5
10
15
20
25
30
Triplets Ventricular
Tachycardia
90
95
100
p=0.67
p=1.00
p=0.69
p=0.80
Treatment group
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s
(%
)
Fig. 1 The prevalence of triplets and ventricular tachycardias between
the treatment groups. BMMC 0 Bone Marrow-derived Mononuclear
Cells, PBMC 0 Peripheral Blood-derived Mononuclear Cells, PCI 0
Percutaneous coronary intervention. P-values are calculated by com-
paring treatment group vs. control
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intracoronary infusion of mononuclear cells does not impose
additional dangers with regard to ventricular arrhythmias.
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